Literature DB >> 26855728

The Economic Aspects of Medical Biotechnology.

Shahin Akhondzadeh.   

Abstract

Entities:  

Year:  2016        PMID: 26855728      PMCID: PMC4717460     

Source DB:  PubMed          Journal:  Avicenna J Med Biotechnol        ISSN: 2008-2835


× No keyword cloud information.
The biotechnology industry has grown rapidly in recent years, doubling in size between 2004 and 2014. Much attention is given to the potential of the biotechnology industry, from drugs and environmental products currently in the pipeline. These products have the potential to generate tremendous opportunities for society, by improving the quality of health care and producing a cleaner environment. Over the past few decades biotechnology sometimes described as the oldest profession in the world has evolved into a modern technology without which medical progress would be scarcely imaginable. Modern biotechnology plays a crucial role both in the elucidation of the molecular causes of disease and in the development of new diagnostic methods and better targeted drugs. Diagnosis and treatment are thus becoming increasingly intertwined. When a disease, rather than being diagnosed on the basis of more or less vague signs and symptoms, can be detected on the basis of molecular information, the possibility of successful treatment depends largely on what diagnostic techniques are available. Biotechnology is an important component of the worldwide economy, and could take on an increasingly significant role as the industry continues to develop. The economic impact of biotechnology as a distinct industry is currently difficult to evaluate because of the manner in which data is collected; however, it is possible to calculate the combined impact of the biotech and pharmaceutical industries 1,2.
  2 in total

1.  Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial.

Authors:  Seyed Mohammad Reza Hosseini; Mehdi Farokhnia; Farzin Rezaei; Amirhossein Gougol; Habibeh Yekehtaz; Negar Iranpour; Bahman Salehi; Mina Tabrizi; Masih Tajdini; Ali Ghaleiha; Shahin Akhondzadeh
Journal:  Eur Neuropsychopharmacol       Date:  2014-02-25       Impact factor: 4.600

2.  Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study.

Authors:  Amirhossein Modabbernia; Farzin Rezaei; Bahman Salehi; Morteza Jafarinia; Mandana Ashrafi; Mina Tabrizi; Seyed M R Hosseini; Masih Tajdini; Ali Ghaleiha; Shahin Akhondzadeh
Journal:  CNS Drugs       Date:  2013-01       Impact factor: 5.749

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.